Document is current

Article History

Received: 25 July 2023

Accepted: 26 October 2023

First Online: 10 November 2023

Competing interests

: P.N.B. acknowledges consulting fees from Resolution Therapeutics and payment or honoraria from Takeda, outside of the submitted work. S.Z.-S. has given presentations for and received support for attending meetings and/or travel from AbbVie, outside of the submitted work. Z.M.Y. acknowledges consulting fees from Gilead, Intercept, Siemens, Novo Nordisk, Madrigal, Merck, Quest and Bristol Myers Squibb, outside of the submitted work. A.M.A. acknowledges grant support to her institution from the US National Institutes of Health (NIH) (DK128127), Novo Nordisk, Pfizer and Target Pharma and advisory board participation for Novo Nordisk, outside of the submitted work. A.M.A. is also a guest editor for <i>Communications Medicine</i><i>,</i> but was not involved in the editorial review of nor the decision to publish this article. J.V.L. acknowledges grants and speaker fees from AbbVie, Gilead Sciences, MSD and Roche Diagnostics to his institution, speaker fees from Echosens, Janssen, Novo Nordisk and ViiV and consulting fees from GSK and Novavax, outside of the submitted work. D.I.-W., C.J.K. and K.R.F. have no potential competing interest to disclose.